ClinicalTrials.Veeva

Menu

A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

Pfizer logo

Pfizer

Status

Enrolling

Conditions

Atopic Dermatitis

Treatments

Drug: CIBINQO

Study type

Observational

Funder types

Industry

Identifiers

NCT05387980
B7451055

Details and patient eligibility

About

The purpose of this study is to learn about the safety and effectiveness (how well the study treatment works) of the study medicine (CIBINQO) for the potential treatment of atopic dermatitis in people under Japanese medical practice.

Enrollment

1,200 estimated patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Participants receiving this Product for treatment of AD.
  2. Participants start receiving this Product (commercial product) for the first time and no earlier than the contract date of this Study, or Participants who continues to receive this drug after hospital transfer can be registered retrospectively.

Exclusion criteria

  1. Participants previously enrolled in this Study at the same site.

Trial design

1,200 participants in 1 patient group

Patients receiving CIBINQO
Description:
Patients receiving CIBINQO tablets by mouth for the treatment of Atopic Dermatitis.
Treatment:
Drug: CIBINQO

Trial contacts and locations

1

Loading...

Central trial contact

Pfizer CT.gov Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems